Sonnet Bio's Interleukin 12 Candidate For Solid Tumor Shows Encouraging Action Preclinical Studies

Sonnet BioTherapeutics Holdings Inc SONN has a preclinical nonhuman primate GLP repeat-dose study of SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) platform.
The FHAB technology targets the tumor and lymphatic tissue, providing a mechanism for dose sparing.
The study's objectives were to evaluate the toxicity of SON-1010 in the primates using a subcutaneous, repeat-dose regimen at three different dose levels versus untreated controls and to evaluate the potential reversibility of any adverse findings.
The NHP data demonstrates that SON-1010 appears to be safe and is eliciting the expected immune responses.
After repeated administration, no observed adverse event level was more than 50 times the anticipated equivalent human clinical dose in NHP, with no evidence of cytokine release syndrome.
Pharmacokinetic (PK) analysis of serum samples confirmed an enhanced profile of IL12-FHAB over recombinant human IL-12, with a half-life of around 40 hours in NHP.
A significant increase in Interferon-γ, a key pleiotropic cytokine associated with anti-tumor mechanisms, was observed following dosing with IL12-FHAB.
By Day 38, all study subjects recovered to baseline (pre-study) values.
Repeat dosing administration was tolerated at all dose levels examined.
Given that IL12-FHAB has an extended half-life, tolerable doses can be given at longer dosing intervals.
The company will provide GMP material for the initiation of the clinical trial in 2H 2021.
Price Action: SONN shares are up 5.6% at $1.71 during the premarket session on the last check Monday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga